Bhave, Manali A.
Quintanilha, Julia C. F.
Tukachinsky, Hanna
Li, Gerald
Scott, Takara
Ross, Jeffrey S.
Pasquina, Lincoln
Huang, Richard S. P.
McArthur, Heather
Levy, Mia A.
Graf, Ryon P.
Kalinsky, Kevin
Funding for this research was provided by:
Foundation Medicine
Article History
Received: 11 March 2024
Accepted: 14 May 2024
First Online: 14 June 2024
Declarations
:
: Financial disclosures: JCFQ, HT, GL, TS, JSR, LP, RSPH, MAL, and RPG are employees of Foundation Medicine, a wholly owned subsidiary of Roche and have equity interest in Roche. MB has consulted for Merck, Gilead, DSI, AstraZeneca, Pfizer, and Eli Lilly. JSR has consulted and owns equity in Celsius Therapeutics and Tango Therapeutics. HMC has consulted for Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Pfizer, Puma, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Peregrine, Calithera, Daiichi-Sankyo, Seattle Genetics, AstraZeneca, Gilead, Crown Bioscience, and TapImmune and has research supported by Bristol-Myers Squibb; MedImmune, LLC/AstraZeneca; BTG; and Merck. KK has consulting or advisory role for Merck, Lilly, Novartis, AstraZeneca, Genentech/Roche, Immunomedics, Seattle Genetics, Oncosec, 4D pharma, Daiichi-Sankyo, Puma Biotechnology, Mersana, Menarini Silicon Biosystems, Myovant Sciences, and Takeda. Research funding (institution) from Novartis, Ascentage, Genentech/Roche, Lilly, Seattle Genetics, AstraZeneca, and Daiichi-Sankyo.